Tacrolimus and mycophenolate mofetil in corticosteroid-resistant hepatitis secondary to tislelizumab: a case report
Tislelizumab is a monoclonal antibody with high binding affinity for programmed death-1 (PD-1) receptors. In patients with extensive-stage small-cell lung cancer (ES-SCLC), the first-line use of tislelizumab combined with chemotherapy has shown significant efficacy. However, with the widespread use...
Saved in:
Main Authors: | Chang Jiang, Shanxian Guo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1385794/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mycophenolate Mofetil and Clostridium difficile-associated Colitis
by: A. I. Dolgushina, et al.
Published: (2021-12-01) -
Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis
by: Božić-Majstorović Ljubinka, et al.
Published: (2024-01-01) -
Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients
by: Alan D. Kaye, et al.
Published: (2024-12-01) -
LESIONS OF THE HEMATOPOIETIC SYSTEM IN A PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND THE EFFECTIVENESS OF TREATMENT WITH MYCOPHENOLATE MOFETIL
by: I.A. Mormol, et al.
Published: (2022-12-01) -
Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus
by: Li X, et al.
Published: (2025-01-01)